TLR Ligands That Stimulate the Metabolism of Vitamin D3 in Activated Murine Dendritic Cells Can Function As Effective Mucosal Adjuvants to Subcutaneously Administered Vaccines
Overview
Affiliations
Cathelicidin production by human myeloid cells stimulated through toll-like receptor (TLR) 2/1, the migration of human CD8+ T cells to inflamed skin sites, and the ability of murine dendritic cells (DCs) to migrate from skin sites of vaccination to mucosal lymphoid organs all occur via calcitriol-dependent mechanisms. Herein, we report that murine DCs exposed to TLR3/TLR4 ligands upregulate their expression of 1 alpha-hydroxylase, the enzyme that converts circulating 25(OH)D3 to calcitriol, the active form of vitamin D3. TLR3/TLR4 ligands injected subcutaneously affect DC migration in vivo, allowing their trafficking to both draining and non-draining systemic and mucosal lymphoid organs. Subcutaneously delivered vaccines containing TLR3/TLR4 ligands and antigen stimulate the induction of both systemic and mucosal immune responses. Vaccines containing TLR9 ligands fail to stimulate 1 alpha-hydroxylase protein expression, are incapable of redirecting DC migration into Peyer's patches and do not induce mucosal immune responses. These findings support a hypothesis that active metabolites of vitamin D3 produced locally are able to affect various aspects of innate and acquired immune responses.
Kim S, Chae C Vaccines (Basel). 2024; 12(7).
PMID: 39066360 PMC: 11281628. DOI: 10.3390/vaccines12070723.
Dabrowska-Leonik N, Sawicka-Powierza J, Bernatowska E, Pac M, Bernat-Sitarz K, Heropolitanska-Pliszka E PLoS One. 2022; 17(11):e0277473.
PMID: 36355809 PMC: 9648759. DOI: 10.1371/journal.pone.0277473.
Vitamin D: A Potential Mitigation Tool for the Endemic Stage of the COVID-19 Pandemic?.
Noriega D, Savelkoul H Front Public Health. 2022; 10:888168.
PMID: 35757617 PMC: 9226430. DOI: 10.3389/fpubh.2022.888168.
Kanai D, Wakui H, Haze T, Azushima K, Kinguchi S, Tsukamoto S Clin Exp Nephrol. 2022; 26(10):988-996.
PMID: 35751753 PMC: 9244285. DOI: 10.1007/s10157-022-02243-8.
The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients.
Zitt E, Davidovic T, Schimpf J, Abbassi-Nik A, Mutschlechner B, Ulmer H Front Immunol. 2021; 12:704773.
PMID: 34220867 PMC: 8242233. DOI: 10.3389/fimmu.2021.704773.